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Aims: Long-acting natriuretic peptide (LANP) is one of the peptide hormones in atrial natriuretic peptide (ANP) pro-
hormone. Low levels of natriuretic peptide may lead to reduced lipolysis and excessive weight gain in obese
patients. The aim of this study was to investigate the relationship between fasting serum LANP level and the
metabolic syndrome (MetS) among congestive heart failure (CHF) patients.
Methods: Fasting blood samples were obtained from 186 patients with normal renal function in cardiac clinic
outpatients. CHF defined by the American College of Cardiology Foundation and the American Heart Association
2005 Guidelines. MetS and its components were defined using diagnostic criteria from the International Diabetes
Federation.
Results: Ninety-eight patients (52.7%) had CHF. There was a tendency of increased fasting LANP levels as the NYHA
CHF functional classes increased (p = 0.002). Forty-six of the CHF patients (46.9%) had MetS. Fasting LANP level
negatively correlated with MetS among CHF patients (p < 0.001). Univariate linear regression analysis showed that
BUN (p = 0.026) positively correlated with fasting serum LANP levels, while body weight (p = 0.009), BMI (p = 0.004),
homeostasis model assessment of insulin resistance (HOMA-IR; p = 0.024) and HOMA-β (p = 0.001) negatively
correlated with fasting serum LANP levels among the CHF patients. Multivariate forward stepwise linear regression
analysis of the significant variables showed that the HOMA-β (R2 change = 0.292, p < 0.001) and HOMA-IR (R2
change = 0.081, p = 0.019) were independent predictors of fasting serum LANP levels in CHF patients.
Conclusions: LANP level is significantly reduced in CHF patients affected by MetS. HOMA-β and HOMA-IR were
independent predictors of serum LANP levels in CHF patients.
Keywords: Long-acting natriuretic peptide, Congestive heart failure, Metabolic syndrome, Homeostasis model
assessment of insulin resistanceIntroduction
There are four peptide hormones derived from the 126-
amino acid atrial natriuretic peptides (ANP) pro-hormone:
long-acting natriuretic peptide (LANP; N-terminal pro-
ANP 1–30), vessel dilator (N-terminal pro-ANP 31–67),
kaliuretic peptide (N-terminal pro-ANP 79–98), and ANP
(α-ANP) and these peptide hormones have significant diu-
retic, natriuretic, and blood-pressure-lowering properties
in animals and humans [1]. The biologic effects of the four* Correspondence: gee.lily@msa.hinet.net
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reproduction in any medium, provided the orpeptide hormones from ANP pro-hormone include vaso-
dilation mediated via enhancing guanylate cyclase activity,
with a resultant increase in the intracellular messenger
cyclic guanosine monophosphate (cGMP), and inhibit the
vasoconstrictive peptide endothelin [2]. ANP also activates
cGMP-dependent protein kinase, leading to perilipin and
hormone-sensitive lipase phosphorylation, and induces
lipolysis [3]. ANP is rapidly cleared from the circula-
tion with a half-life of 3–4 minutes. No receptors for
N-terminal pro-ANP are known today; therefore this pep-
tide circulates longer which leads to significant higher
concentrations in blood compared to ANP. Thus, circula-
ting levels of N-terminal pro-ANP are less sensitive to thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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levels of ANP secretion than the rapidly fluctuating levels
of ANP [1,2].
The metabolic syndrome (MetS) is associated with in-
creased cardiovascular events [4]. The prevalence of
MetS among congestive heart failure (CHF) patients was
more than double compared with that in the general
population in Japan [5]. A recent study noted that MetS
predicted CHF independent of interim myocardial in-
farction and prevalent diabetes in elderly Finns during a
20-year follow-up [6]. CHF was also associated with in-
sulin resistance independent of diabetes mellitus in a
large community-based sample of elderly men [7]. It can
be speculated that low levels of natriuretic peptide may
lead to reduced lipolysis and excessive weight gain in
obese patients, which may be one of the biological al-
terations that contribute to the development of obesity
[8]. Lower plasma N-terminal pro-ANP levels were also
associated with the development of insulin resistance
(HOMA-IR) and MetS [9]. LANP is one of the N-terminal
pro-ANP. There is no study about the association between
serum LANP levels and MetS in CHF patients. The aim of
this study was to investigate the relationship between
fasting serum LANP level and the MetS among CHF
patients.Material and methods
Patients
Between October 2009 and December 2009, 186 con-
secutive clinic outpatients in a medical center in Hualien,
eastern Taiwan (80 males and 106 females, age range 37–
88 years) were enrolled into this study. The Protection
of the Human Subjects Institutional Review Board of
Tzu-Chi University and Hospital approved this study. Pa-
tients were excluded if they had any acute infection, acute
myocardial infarction, pulmonary edema, liver cirrhosis,
thyroid disease, chronic renal failure (serum creatinine
≥1.2 mg/dl) at the time of blood sampling or if they re-
fused to provide informed consent for the study.Definition of CHF
In the present study, we included patients with stages
C/D CHF defined by the American College of Cardio-
logy Foundation and the American Heart Association
2005 Guidelines. Heart failure is a complex clinical syn-
drome that can result from any structural or functional
cardiac disorder that impairs the ability of the ventricle
to fill with or eject blood [10]. New York Heart Associ-
ation (NYHA) CHF functional classes were collected
from the medical records. According to the European
Society of Cardiology 2007 Guidelines, we further divi-
ded them into 2 groups: heart failure with preserved
ejection fraction (HFPEF; LV ejection fraction (EF)≥50%) and heart failure with reduced ejection fraction
(HFREF; LVEF <50%) [11].
Anthropometric analysis
Body weight was measured to the nearest half-kilogram
with the patient in light clothing and without shoes.
Height was measured to the nearest half centimeter. Waist
circumference was measured in a horizontal plane, mid-
way between the inferior margin of the ribs and the super-
ior border of the iliac crest. Body mass index (BMI) was
calculated as weight (kilograms) divided by height squared
(meters). Bioimpedance measurements of fat mass were
performed at the bedside according to the standard,
tetrapolar, whole body (hand-foot) technique, using a
single-frequency (50-kHz) analyzer (Biodynamic-450, Bio-
dynamics Corporation, Seattle, MA, USA). Measurements
were carried out by the same operator; fat mass was col-
lected and analyzed by specific formulas provided by the
manufacturer [12-15].
Biochemical investigations
Fasting blood samples of approximately 0.5 ml for meas-
uring complete blood count (Sysmex K-1000, Bohemia,
NY, USA) and other factors were immediately centri-
fuged at 3000 g for 10 min. Serum levels of blood urea
nitrogen (BUN), creatinine (Cre), fasting glucose, to-
tal cholesterol (TCH), triglyceride (TG), high-density
lipoprotein-cholesterol (HDL-cholesterol), low-density
lipoprotein-cholesterol (LDL-cholesterol), albumin, globu-
lin, and C-reactive protein (CRP) were measured using an
autoanalyzer (COBAS Integra 800, Roche Diagnostics,
Basel, Switzerland). Serum LANP (N-terminal pro-ANP
1–30 or pre-pro-ANP 26–55, Phoenix Pharmaceuticals
Inc., Burlingame, CA, USA) levels were measured using a
commercial available enzyme immunoassay kit (EIA). The
limit of detection calculated as the concentration of hu-
man LANP corresponding to the blank average minus
three standard deviations was 0.1 ng/ml. The inter- and
intra-assay coefficients of variation for LANP were 6.2%
and 5.4%, respectively [12]. Serum insulin levels were
measured using the MEIA (microparticle enzyme immu-
nosobent assay) method by an autoanalyzer (Abbott
Laboratories, Abbott Park, IL, USA). Insulin resistance
was evaluated using a homeostasis model assessment of
insulin resistance (HOMA-IR) as follows: HOMA-IR =
fasting plasma glucose (mg/dl) × fasting serum insulin
(μU/ml)/405 [15]. HOMA-β (pancreatic β-cell function)
was calculated using the following formula: HOMA-β =
fasting serum insulin (μU/ml) × 360/fasting plasma glu-
cose (mg/dl) − 63 [16].
Metabolic syndrome and its components
The prevalence of MetS was defined using the Inter-
national Diabetes Federation definition [17]. People were
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obesity with a waist circumference ≥90 cm (men) or
≥80 cm (women) (Chinese criteria), and were matching
two or more of the following criteria: fasting serum glu-
cose of 110 mg/dl or more, triglycerides of 150 mg/dl or
higher, HDL-cholesterol level less than 40 mg/dl in men
or less than 50 mg/dl in women, or blood pressure of
130/85 mmHg or higher. The use of antihypertensive
medication was considered as high blood pressure in this
analysis. Type 2 diabetes was determined according to
World Health Organization criteria [18]. A person was
regarded as diabetic if the fasting plasma glucose was
either 126 mg/dl or more, or if the 2 h glucose during
an oral glucose tolerance test was 200 mg/dl or more, or
if he/she was using diabetes medication (oral or insulin).
Statistical analysis
Data are expressed as means ± standard deviation (SD)
and were tested for normal distribution by Kolmogorov-
Smirnov statistics. Categorical variables were analyzed byTable 1 Clinical variables of the patients with or without cong
Items No CHF (n = 88)
Age (years) 62.45 ± 7.75
Height (cm) 158.35 ± 6.98
Body weight (kg) 71.62 ± 10.48
Waist circumference (cm) 95.11 ± 8.74
Body mass index (BMI; kg/m2) 28.57 ± 3.79
Body fat mass (%) 36.19 ± 7.36
White blood count (x1000/ul) 7.01 ± 1.99
Haemoglobulin (g/dl) 13.64 ± 1.82
Albumin (g/dl) 4.50 ± 0.27
Globulin (g/dl) 2.90 ± 0.48
Total cholesterol (mg/dl) 191.66 ± 43.62
Triglyceride (mg/dl) 150.77 ± 84.21
HDL-C (mg/dl) 48.05 ± 13.87
LDL-C (mg/dl) 127.00 ± 43.38
Fasting glucose (mg/dl) 117.73 ± 34.78
Blood urea nitrogen (mg/dl) 16.16 ± 4.58
Creatinine (mg/dL) 0.81 ± 0.20
CRP (mg/dl) 0.28 ± 0.26
Systolic pressure (mmHg) 130.88 ± 7.32
Diastolic pressure (mmHg) 74.49 ± 8.10
Insulin (μU/dl) 11.22 ± 10.85
HOMA-IR 3.08 ± 2.59
HOMA-β 115.55 ± 165.54
LANP (ng/ml) 2.25 ± 2.01
*P < 0.05 was considered statistically significant after performing the Student t-test or
CHF, congestive heart failure; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low
homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model athe Chi-square test. Comparisons between patients were
performed using Student’s independent t test (two-tailed)
for the normally distributed data or the Mann–Whitney
U test for the parameters that presented with non-normal
distribution (fasting glucose, CRP, LANP). The significance
of differences of LANP between groups (NYHA functional
CHF classes) was analyzed by the Kruskal-Wallis analysis
of variance (AVONA) test. Clinical variables that corre-
lated with serum LANP levels in CHF patients were evalu-
ated by univariate linear regression analyses. Variables that
were significantly associated with LANP in CHF patients
were tested for independency in multivariate forward step-
wise regression analysis. Data were analyzed using SPSS
for Windows (version 13.0; SPSS Inc., Chicago, IL, USA).
A p-value < 0.05 was considered statistically significant.
Results
The clinical characteristics of the patients with or without
CHF are presented in Table 1. Ninety-eight patients
(52.7%) had CHF (64 dilated cardiomyopathy, 24 ischemicestive heart failure
CHF (n = 98) P value
66.73 ± 11.19 0.037*
160.06 ± 7.73 0.268
72.39 ± 13.53 0.761
96.99 ± 10.25 0.384
28.09 ± 3.85 0.547
36.91 ± 6.89 0.634
6.91 ± 1.75 0.805
13.86 ± 1.65 0.549
4.43 ± 0.24 0.241
2.94 ± 0.41 0.608
192.82 ± 34.03 0.886
161.10 ± 95.39 0.585
45.53 ± 12.74 0.365
124.94 ± 29.83 0.788
123.45 ± 69.92 0.590
17.18 ± 4.96 0.310
0.85 ± 0.18 0.202
0.40 ± 0.59 0.972
131.35 ± 11.26 0.819
75.06 ± 7.60 0.730
11.11 ± 7.95 0.462
3.50 ± 3.68 0.620
94.43 ± 65.74 0.358
3.77 ± 4.41 0.035*
Mann–Whitney U test (LANP, CRP, fasting glucose, insulin, HOMA-IR, HOMA-β).
-density lipoprotein-cholesterol; CRP, C-reactive protein; HOMA-IR,
ssessment of beta cell function; LANP, long-acting natriuretic peptide.
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tients had older age (p = 0.037) and higher LANP level
(p = 0.035) than patients without CHF. There was no dif-
ference of the fasting serum LANP levels (p = 0.090) be-
tween HFREF patients (n = 24; 4.82 ± 3.37 ng/ml) and
HFPEF patients (n = 74; 3.03 ± 2.84 ng/ml). However,
there was a tendency toward increased fasting LANP le-
vels as the NYHA CHF functional classes increased in
CHF patients (p = 0.002; Figure 1). The highest value of
the fasting LANP level was noted with NYHA CHF func-
tional class IV (11.57 ± 1.68 ng/ml) and the lowest value of
the fasting LANP level was noted with NYHA CHF func-
tional class I (0.97 ± 0.61 ng/ml). Although, there is a ten-
dency of lower serum LANP levels in patients with MetS
than without MetS according the various CHF classes
(I-IV). LANP levels in patients with MetS than without
MetS did not differ statistically according the various CHF
classes (Table 2).
The clinical characteristics and fasting serum LANP
levels of the CHF patients are presented in Table 3. Forty-
six CHF patients (46.9%) had MetS, whereas the re-
maining 52 patients (53.1%) did not. CHF patients who
had MetS had lower serum fasting LANP levels than those
without MetS (p < 0.001). LANP levels did not differ sta-
tistically by gender distribution, diabetes, hypertension,
hyperlipidemia, ARB, ACEI, CCB, β-blocker, thiazide, sta-
tin, fibrate, sulfaurea, metformin, aspirin, or clopidogrel
drugs used.
The univariate linear analysis of fasting serum LANP
levels in CHF patients is presented in Table 4. BUN (r =
0.317; p = 0.026) positively correlated with fasting serum
LANP levels, while body weight (r = −0.370; p = 0.009),
BMI (r =−0.407; p = 0.004), HOMA-IR (r = −0.321; p =
0.024) and HOMA-β (r = −0.469; p = 0.001) negativelyFigure 1 Fasting serum long-acting natriuretic peptide levels in
New York Heart Association functional classes among the 98
congestive heart failure patients. Data was analyzed by the
Kruskal-Wallis analysis of variance (AVONA) test.correlated with fasting serum LANP levels among the CHF
patients.
Multivariate forward stepwise linear regression analysis
of the variables that were significantly associated with
fasting serum LANP levels among CHF patients showed
that HOMA-β (β = −0.486, R2 change = 0.292, p < 0.001)
and HOMA-IR (β = −0.289, R2 change = 0.081, p = 0.019)
were the independent predictors of fasting serum LANP
levels (Table 5).
Discussion
The results of our study showed that the fasting LANP
level was negatively associated with MetS in CHF patients.
Pancreatic beta cell function and insulin resistance were
independent predictors of the serum LANP level among
CHF patients.
Cardiac natriuretic peptides consist of a family of six
peptide hormones that are synthesized by three separate
genes and then stored as three separate pro-hormones
(i.e. 126-amino acid atrial natriuretic peptide (ANP),
108-amino acid B-type natriuretic peptide (BNP) and
103-amino acid C-type natriuretic peptide (CNP) pro-
hormones). The ANP pro-hormone contains four pep-
tide hormones: LANP, vessel dilator, kaliuretic peptide
and ANP [1]. Cardiac natriuretic peptides are known to
play a key role in the regulation of salt and water bal-
ance and blood pressure homeostasis [19]. High plasma
level of LANP was detected in CHF patients and in-
creased in patients of NYHA CHF functional classes II
and III [20]. Our study also noted CHF patients had
higher LANP levels and noted a tendency for increasing
fasting LANP levels as the NYHA CHF functional clas-
ses increased in CHF patients. The highest value of the
fasting LANP level was noted in NYHA CHF functional
class IV, and the lowest value was noted in NYHA CHF
functional class I.
MetS represents a constellation of hypertension, abdom-
inal obesity, impaired fasting glucose, and dyslipidaemia,
and it has been shown to be a risk factor for cardiovascu-
lar disease [17]. CHF is associated with insulin resistance
independent of diabetes mellitus, and the prevalence of
MetS is high in CHF patients [5,7,21]. It is conceivable
that the increased prevalence of MetS in CHF patients is
both the cause and the result of CHF, as activation of both
the sympathetic nervous system and rennin-angiotensin
system causes the metabolic components [22]. Recent
study noted that MetS predicted CHF independent of in-
terim myocardial infarction and prevalent diabetes in eld-
erly Finns, and MetS increases mortality in CHF patients
[6,21]. Natriuretic peptides induce natriuresis and diuresis,
reduce blood pressure, and, moreover, have powerful lipo-
lytic and lipomobilizing activity in humans [23]. At least
two adipocyte lipases are important for controlling lipo-
lysis, hormone-sensitive lipase and adipocyte triglyceride
Table 2 Serum long-acting natriuretic peptide levels in the various congestive heart failure classes (I-IV) in patients
with and without metabolic syndrome
Characteristic CHF class I (n = 6) CHF class II (n = 70) CHF class III (n = 18) CHF class IV (n = 4)
Metabolic syndrome No 1.14 ± 0.75 3.48 ± 2.19 6.99 ± 2.98 11.57 ± 1.68
Yes 0.89 ± 0.52 1.90 ± 1.15 1.57 ± 0.90 0
P value 0.812 0.096 0.111
Data are expressed as means ± standard deviations.
* P < 0.05 was considered statistically significant after Mann–Whitney U test.
Table 3 Clinical characteristics and fasting serum long-acting natriuretic peptide levels of 98 congestive heart failure
patients
Characteristic Number (%) LANP (ng/ml) P value
Gender Male 46 (46.9) 3.07 ± 2.59 0.589
Female 52 (53.1) 4.39 ± 5.53
Diabetes No 60 (61.2) 3.32 ± 2.78 0.886
Yes 38 (38.8) 4.48 ± 6.21
Hypertension No 28 (28.6) 5.04 ± 7.04 0.626
Yes 70 (71.4) 3.26 ± 2.76
Hyperlipidaemia No 32 (32.7) 5.18 ± 6.59 0.376
Yes 66 (67.3) 3.09 ± 2.72
Metabolic syndrome No 52 (53.1) 5.51 ± 5.44 <0.001*
Yes 46 (46.9) 1.80 ± 1.09
Angiotensin-converting enzyme inhibitor use No 68 (69.4) 3.58 ± 4.68 0.786
Yes 30 (30.6) 4.20 ± 3.84
Angiotensin receptor blocker use No 62 (63.3) 4.17 ± 5.28 0.820
Yes 36 (36.7) 3.09 ± 2.22
β-blocker use No 46 (46.9) 4.07 ± 5.78 0.548
Yes 52 (53.1) 3.51 ± 2.79
Calcium channel blocker use No 58 (59.2) 4.49 ± 5.35 0.263
Yes 40 (40.8) 2.73 ± 2.26
Fibrate use No 94 (95.9) 3.86 ± 4.48 0.511
Yes 4 (4.1) 1.66 ± 0.17
Statin use No 76 (77.6) 3.82 ± 4.80 0.573
Yes 22 (22.4) 3.61 ± 2.86
Thiazide use No 48 (49.0) 2.96 ± 2.54 0.548
Yes 50 (51.0) 4.55 ± 5.61
Sulfaurea use No 92 (93.9) 3.81 ± 4.54 0.677
Yes 6 (6.1) 3.23 ± 1.57
Metformin use No 82 (83.7) 3.44 ± 2.91 0.935
Yes 16 (16.3) 5.49 ± 9.01
Aspirin use No 56 (57.1) 3.87 ± 5.28 0.585
Yes 42 (42.9) 3.64 ± 3.01
Clopidogrel use No 86 (87.8) 3.80 ± 4.631 0.474
Yes 12 (12.2) 3.59 ± 2.59
Data are expressed as means ± standard deviations.
* P < 0.05 was considered statistically significant after Mann–Whitney U test.
Wang et al. Diabetology & Metabolic Syndrome 2013, 5:19 Page 5 of 8
http://www.dmsjournal.com/content/5/1/19
Table 4 Correlation of fasting serum long-acting
natriuretic peptide levels and clinical variables by
univariate linear regression analyses among the 98
congestive heart failure patients
Items Beta P value
Age (years) 0.214 0.140
Height (cm) −0.070 0.633
Body weight (kg) −0.370 0.009*
Waist circumference (cm) −0.259 0.103
Body mass index (BMI; kg/m2) −0.407 0.004*
Body fat mass (%) −0.092 0.840
Duration of heart failure (months) 0.050 0.765
White blood count (x1000/ul) −0.042 0.788
Haemoglobulin (g/dl) −0.067 0.668
Albumin (g/dl) −0.100 0.494
Globulin (g/dl) −0.058 0.692
Total cholesterol (mg/dl) −0.042 0.776
Triglyceride (mg/dl) −0.248 0.086
HDL-C (mg/dl) 0.010 0.948
LDL-C (mg/dl) 0.061 0.679
Fasting glucose (mg/dl) 0.218 0.132
Blood urea nitrogen (mg/dl) 0.317 0.026*
Creatinine (mg/dl) −0.018 0.903
CRP (mg/dl) −0.162 0.265
HOMA-IR −0.321 0.024*
HOMA-β −0.469 0.001*
*P < 0.05 was considered statistically significant after univariate linear analyses.
HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-
cholesterol; CRP, C-reactive protein; HOMA-IR, homeostasis model assessment
of insulin resistance; HOMA-β, homeostasis model assessment of beta
cell function.
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droplet surface are master regulators of lipolysis,
protecting or exposing the triglyceride core of the droplet
to lipases [24]. ANP increases the intracellular cyclic
guanosine monophosphate (cGMP) concentration, which
activates cGMP-dependent protein kinase, leading to
perilipin and hormone-sensitive lipase phosphorylation,
and induces lipolysis [3,25]. Lower plasma N-terminalTable 5 Multivariate stepwise linear regression analysis
of body weight, body mass index, blood urea nitrogen,
HOMA-IR and HOMA-β: correlation to fasting serum long-
acting natriuretic peptide among 98 congestive heart
failure patients
Items Beta R square R square change P value
HOMA-β −0.486 0.292 0.292 < 0.001*
HOMA-IR −0.289 0.373 0.081 0.019*
*P <0.05 was considered statistically significant after multivariate stepwise
linear regression analyses.
HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β,
homeostasis model assessment of beta cell function.proatrial natriuretic peptide levels were associated with
the development of MetS [9]. ANP increases the produc-
tion of adiponectin by human adipocytes, as well as in pa-
tients with CHF [26]. Serum adiponectin values were
found to correlate inversely with the presence of MetS
[14,15]. Our study also noted that CHF patients with MetS
had lower fasting serum LANP levels.
Human studies indicated that ANP is removed by the
lung, kidney, and liver and degraded by natriuretic peptide
receptor-C (NPRC), neprilysin, and insulin-degrading en-
zyme [27]. The reduced glomerular filtration rate may
contribute to raise ANP levels through a reduced renal
clearance of the peptides [28]. Our study found that BUN
positively correlated with fasting serum LANP levels a-
mong the CHF patients. Obese individuals in the cohorts
of the Framingham Heart Study were found to have lower
plasma N-terminal pro-atrial natriuretic peptide levels
than those with normal weight [29]. N-terminal pro-atrial
natriuretic peptide was also inversely correlated with BMI
in a survey of adult male population from Southern Italy
[30]. Our study also found that body weight and BMI
negatively correlated with fasting serum LANP levels
among CHF patients. ANP increased in pancreatic β-cell
death was observed in ANP-treated BRIN-BD11 β-cells
[31]. Long-term treatment with ANP inhibited ATP pro-
duction and insulin secretion in rat pancreatic islets [32].
Lower plasma N-terminal pro-ANP levels were associated
with the development of insulin resistance in humans [9].
Our study also showed that HOMA-IR, and HOMA-β
negatively correlated with fasting serum LANP levels
among CHF patients. The multivariate forward stepwise
linear regression analysis of the significant variables
showed that HOMA-β and HOMA-IR were the inde-
pendent predictors of fasting serum LANP levels in our
study.
Our study noted low levels of LANP in CHF patients
may lead to decreased lipolysis and this may be linked to
the development of MetS and noted a tendency for in-
creasing fasting LANP levels as the NYHA CHF func-
tional classes increased in CHF patients. Our study also
found that BMI negatively correlated with fasting serum
LANP levels among CHF patients. MetS is associated
with increased cardiovascular events [4]. Numerous stu-
dies have documented an obesity paradox, in which
overweight and obese people with CHF have a better
prognosis than patients who are not overweight or obese
[33-35]. The reasons for the obesity paradox in CHF re-
main unclear. The complex constellation of physical,
metabolic, neuronal, and hormonal alterations in obesity
may lead to structural and functional alterations in the
heart [33]. There is a need for prospective studies to elu-
cidate mechanisms for this relationship.
Many factors may affect serum LANP levels, such as
drugs, clearance of LANP, and associated diseases. Type
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ology that develops in response to genetic and environ-
ment influences. The pathophysiology of type 2 DM is
characterized by impaired insulin secretion, peripheral
insulin resistance and excessive hepatic glucose produc-
tion [18]. Although our study noted LANP level was sig-
nificantly negatively related to the pancreatic beta cell
function and insulin resistance in CHF patients. How-
ever, LANP levels did not differ statistically by diabetes
in this study. Many factors such as excessive hepatic glu-
cose production, case numbers, and drugs may affect the
result. Pharmacological interventions have been shown
to influence serum ANP in humans. Beta-receptor an-
tagonists appear to augment plasma ANP and cGMP
concentrations [36]. Initiation of atorvastatin in the early
phase of an acute myocardial infarction has beneficial ef-
fects on decreasing ANP level after 24 weeks treatment
[37]. Pioglitazone does not alter the circulating levels of
ANP in type II diabetes mellitus patients [38]. Our re-
sults did not show a relationship between statins or per-
oxisome proliferator-activated receptor γ agonists or
other drugs (angiotensin receptor blocker, angiotensin-
converting enzyme inhibitor, calcium channel blocker, or
thiazide diuretic) and serum LANP among CHF patients.
Further studies are required to elucidate the relationship
between medication and LANP in CHF patients.
Our study has some limitations. Firstly, this study was
of cross-sectional design. Therefore, our findings should
be investigated in long-term prospective studies before a
causal relationship between serum LANP and MetS in
CHF patients can be established. Secondly, most studies
have focused on ANP effects on lipolysis and adipose tis-
sue. However, lack of LANP effects has been investi-
gated. Thirdly, other N-terminal ANP pro-hormone
peptides such as vessel dilator or kaliuretic peptide have
the same effects as LANP also needed further investigated.
Further studies are needed to show the N-terminal ANP
pro-hormone peptides effects on MetS in CHF patients.
Conclusion
The present study shows there was a tendency of in-
creased fasting LANP levels as the NYHA CHF functional
classes increased and a negative association between cir-
culating fasting LANP and MetS among CHF patients.
HOMA-β and HOMA-IR were independent predictors of
the serum LANP level among the CHF patients. LANP
level was significantly negatively related to the pancreatic
beta cell function and insulin resistance in these patients.
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